Adrenomedullin - A potential disease activity marker and suppressor of nephritis activity in systemic lupus erythematosus

Rheumatology

Volumn 45, Issue 10, 2006, Pages 1266-1272

  Mak, A ^a   Cheung, B M Y ^a   Mok, C C ^b   Leung, R ^a   Lau, C S ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b TUEN MUN HOSPITAL   (Hong Kong)

Author keywords

Adrenomedullin; Disease activity; Lupus; Nephritis; Proteinuria

Indexed keywords

ADRENOMEDULLIN; BIOLOGICAL MARKER; COMPLEMENT COMPONENT C3; CREATININE; PREDNISOLONE;

ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMOGRAPHY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HONG KONG; HUMAN; KIDNEY BIOPSY; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROTEINURIA; RADIOIMMUNOASSAY; REGRESSION ANALYSIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADRENOMEDULLIN; ADULT; ANTIBODIES, ANTINUCLEAR; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; FEMALE; GLUCOCORTICOIDS; HEALTH STATUS INDICATORS; HUMANS; KIDNEY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; MIDDLE AGED; STATISTICS, NONPARAMETRIC;

EID: 33749616661     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kel105     Document Type: Article

References (33)

1. Kitamura K, Kangawa K, Kawamoto M et al. Adrenomedullin: A novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 1993;192:553-60.
2. Ichiki Y, Kitamura K, Kangawa K, Kawamoto M, Matsuo H, Eto T. Distribution and characterization of immunoreactive adrenomedullin in human tissue and plasma. FEBS Lett 1994;338:6-10.
3. Ishimitsu T, Nishikimi T, Saito Y et al. Plasma levels of adrenomedullin, a newly identified hypotensive peptide, in patients with hypertension and renal failure. J Clin Invest 1994;94:2158-61.
4. Kinoshita H, Fujimoto S, Kitamura K et al. Increased plasma levels of mature adrenomedullin in chronic glomerulonephritis. Nephron 2000;86:333-8.
5. Kubo A, Iwano M, Minaamino N et al. Measurement of plasma and urinary adrenomedullin in patients with IgA nephropathy. Nephron 1998;78:389-94.
6. Kubo A, Kurioka H, Minamino N et al. Plasma and urinary levels of adrenomedullin in chronic glomerulonephritis patients with proteinuria. Nephron 1998;80:227-30.
7. Nitta K, Kikawada E, Uchida K et al. Plasma levels of the mature form of adrenomedullin and disease activity in patients with IgA nephropathy. Nephron 2000;86:520-1.
8. Cheung B, Leung R. Elevated plasma levels of human adrenomedullin in cardiovascular, respiratory, hepatic and renal disorders. Clin Sci 1997;92:59-62.
9. Sugo S, Minamino N, Shoji H et al. Interleukin-1, tumour necrosis factor and lipopolysaccharide additively stimulate production of adrenomedullin in vascular smooth muscle cells. Biochem Biophys Res Commun 1995;207:25-32.
10. Kubo A, Minamino N, Isumi Y et al. Production of adrenomedullin in macrophage cell line and peritoneal macrophage. J Biol Chem 1998;273:16730-8.
11. Cheung BM, Lau CS, Leung RY. Plasma adrenomedullin level in systemic lupus erythematosus. Rheumatology 2000;39:804-5.
12. Nishitani Y, Kubo A, Iwano M et al. Imbalance between interleukin-6 and adrenomedullin mRNA in peripheral blood mononuclear cells of patients with lupus nephritis. Clin Exp Immunol 2001;124:330-6.
13. Kohno M, Yokokawa K, Yasunari K, Kano H, Horio T, Takeda T. Stimulation of cyclic adenosine monophosphate formation by the novel vasorelaxant peptide adrenomedullin in cultured rat mesangial cells. Metabolism 1995;44:10-2.
14. Matousovic K, Grande JP, Chini CC, Chini EN, Dousa TP. Inhibitors of cyclic nucleotide phosphodiesterase isozymes type-III and type-IV suppress mitogenesis of rat mesangial cells. J Clin Invest 1995;96:401-10.
15. Chini EN, Chini CC, Bolliger C et al. Cytoprotective effects of adrenomedullin in glomerular cell injury: Central role of cAMP signalling pathway. Kidney Int 1997;52:917-25.
16. Kubo A, Nishitani Y, Minamino N et al. Adrenomedullin gene transcription is decreased in peripheral blood mononuclear cells of patients with IgA nephropathy. Nephron 2000;85:201-6.
17. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
18. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
19. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35:630-40.
20. Petri M, Hellmann D, Hochberg M. Validity and reliability of lupus activity measures in the routine clinic setting. J Rheumatol 1992;19:53-9.
21. Hawker G, Gabriel S, Bombardier C, Goldsmith C, Caron D, Gladman D. A reliability study of SLEDAI: A disease activity index for systemic lupus erythematosus. J Rheumatol 1993;20:657-60.
22. Petri M, Genovese M, Engle E, Hochberg M. Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study. Arthritis Rheum 1991;34:937-44.
23. Gladman DD, Goldsmith CH, Urowitz MB et al. Sensitivity to change of 3 Systemic Lupus Erythematosus Disease Activity Indices: International validation. J Rheumatol 1994;21:1468-71.
24. McCluskey RT. Lupus nephritis. In: Sommers SC, ed. Pathology decennial. New York: Appleton-Century-Crofts, 1975:435-60.
25. Dawson B, Trapp RG. Basic & clinical biostatistics, 3rd edn. International edition, The McGraw-Hill Companies Inc., Singapore, 2001:183-210.
26. Sumimoto T, Nishikimi T, Mukai M et al. Plasma adrenomedullin concentrations and cardiac and arterial hypertrophy in hypertension. Hypertension 1997;30:741-5.
27. Kato J, Kitamura K, Uemura T et al. Plasma levels of adrenomedullin and atrial and brain natriuretic peptides in the general population: Their relations to age and pulse pressure. Hypertens Res 2002; 25:887-92.
28. Kohno M, Hanehira T, Kano H et al. Plasma adrenomedullin concentrations in essential hypertension. Hypertension 1996;27:102-7.
29. Mok CC, Lau CS. Pathogenesis of systemic lupus erythematosus. J Clin Pathol 2003;56:481-90.
30. Saito T, Itoh H, Chun TH et al. Coordinate regulation of endothelin and adrenomedullin secretion by oxidative stress in endothelial cells. Am J Physiol Heart Circ Physiol 2001;281:H1364-71.
31. Mok CC. Prognostic factors in lupus nephritis. Lupus 2005;14:39-44.
32. Yamamoto T, Nagase M, Hishida A, Honda N. Interstitial inflammatory and chronic tubulointerstitial lesions in lupus nephritis: Comparison with those in IgA nephropathy. Lupus 1993;2:261-8.
33. Hay EM, Bacon PA, Gordon C et al. The BILAG index: A reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993;86:447-58.